2024
An update on the global disparities in kidney disease burden and care across world countries and regions
Bello A, Okpechi I, Levin A, Ye F, Damster S, Arruebo S, Donner J, Caskey F, Cho Y, Davids M, Davison S, Htay H, Jha V, Lalji R, Malik C, Nangaku M, See E, Sozio S, Tonelli M, Wainstein M, Yeung E, Johnson D, Group I, Abu-Alfa A, Amouzegar A, Anand S, Arogundade F, Ashuntantang G, Bavanandan S, Coppo R, Diongole H, Divyaveer S, Ekrikpo U, Ethier I, Fung W, Gaipov A, Ghimire A, Houston G, Ibrahim K, Irish G, Jindal K, Kelly D, Lightstone L, Madero M, Nalado A, Neuen B, Olanrewaju T, Osman M, Parekh R, Petrova A, Prasad N, Prikhodina L, Racki S, Riaz P, Saad S, Sakajiki A, Savaj S, Shah D, Suzuki Y, Tesar V, Tiv S, Tungsanga S, Tzanno-Martins C, Viecelli A, Wang A, Wong M, Zaidi D. An update on the global disparities in kidney disease burden and care across world countries and regions. The Lancet Global Health 2024, 12: e382-e395. PMID: 38365413, DOI: 10.1016/s2214-109x(23)00570-3.Peer-Reviewed Original ResearchMeSH KeywordsChildCost of IllnessDelivery of Health CareHumansKidneyRenal DialysisRenal Insufficiency, ChronicConceptsConservative kidney managementLow-resource settingsCountry income levelKidney replacement therapyKidney careHealth workforce shortagesWHO building blocksLiterature review of published reportsGlobal Kidney Health AtlasWorld Bank income groupsKidney care deliveryBurden of chronic kidney diseaseBurden of kidney diseaseGlobal burden of kidney diseaseAnnual median costsChronic kidney diseaseHigh-income countriesKidney disease burdenPhases of data collectionPrevalence of chronic kidney diseaseIncome levelPoint of deliveryAffordability of medicinesCare deliveryWorkforce shortages
2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
House A, Wanner C, Sarnak M, Piña I, McIntyre C, Komenda P, Kasiske B, Deswal A, deFilippi C, Cleland J, Anker S, Herzog C, Cheung M, Wheeler D, Winkelmayer W, McCullough P, Participants C, Abu-Alfa A, Amann K, Aonuma K, Appel L, Baigent C, Bakris G, Banerjee D, Boletis J, Bozkurt B, Butler J, Chan C, Costanzo M, Dubin R, Filippatos G, Gikonyo B, Gikonyo D, Hajjar R, Iseki K, Ishii H, Knoll G, Lenihan C, Lentine K, Lerma E, Macedo E, Mark P, Noiri E, Palazzuoli A, Pecoits-Filho R, Pitt B, Rigatto C, Rossignol P, Setoguchi S, Sood M, Störk S, Suri R, Szummer K, Tang S, Tangri N, Thompson A, Vijayaraghavan K, Walsh M, Wang A, Weir M. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 95: 1304-1317. PMID: 31053387, DOI: 10.1016/j.kint.2019.02.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseDialysis-dependent chronic kidney diseaseNondialysis chronic kidney diseaseHeart failureKidney diseaseEjection fractionGlobal outcomeKidney transplant patientsReduced ejection fractionControversies ConferenceTransplant patientsBreakout group discussionsDiseaseOutcomesFailureHFpEFPatientsGroup discussionsPrevalenceIncidenceDiagnosisPreventionDialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Chan C, Blankestijn P, Dember L, Gallieni M, Harris D, Lok C, Mehrotra R, Stevens P, Wang A, Cheung M, Wheeler D, Winkelmayer W, Pollock C, Participants C, Abu-Alfa A, Bargman J, Bleyer A, Brown E, Davenport A, Davies S, Finkelstein F, Flythe J, Goffin E, Golper T, Gómez R, Hamano T, Hecking M, Heimbürger O, Hole B, Hothi D, Ikizler T, Isaka Y, Iseki K, Jha V, Kawanishi H, Kerr P, Komenda P, Kovesdy C, Lacson E, Laville M, Lee J, Lerma E, Levin N, Lichodziejewska-Niemierko M, Liew A, Lindley E, Lockridge R, Madero M, Massy Z, McCann L, Meyer K, Morton R, Nadeau-Fredette A, Okada H, Perez J, Perl J, Polkinghorne K, Riella M, Robinson B, Rocco M, Rosansky S, Rotmans J, Roblero M, Tangri N, Tonelli M, Tong A, Tsukamoto Y, Tungsanga K, Vachharajani T, van Loon I, Watnick S, Weiner D, Wilkie M, Zakharova E. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 96: 37-47. PMID: 30987837, DOI: 10.1016/j.kint.2019.01.017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEnd-stage kidney diseaseDialysis initiationKidney diseaseModality choiceGoals of careNumber of patientsPatient-centered goalsDiverse health care systemsHealth care jurisdictionsAreas of controversyHealth care systemControversies ConferenceMaintenance dialysisDialysis modalityPatient goalsPatient educationIndividualized carePatient involvementPatient experienceGlobal outcomeCare systemDialysisPatientsOutcomesDisease
2008
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*
Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*. Current Medical Research And Opinion 2008, 24: 1091-1100. PMID: 18328118, DOI: 10.1185/030079908x280653.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseErythropoiesis-stimulating agentsHealth-related qualityDarbepoetin alfaWeek 52Week 12Kidney diseasePatients' health-related qualityGeneral CKD populationQ2W darbepoetin alfaWeek darbepoetin alfaGlomerular filtration rateSingle-arm studyBenefits of treatmentMean Hb concentrationYears of ageSubject inclusion criteriaCKD populationCreatinine clearanceHemoglobin levelsHb targetHb levelsHRQOL measuresFiltration rateInclusion criteria
2007
Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
Saab G, Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? American Journal Of Roentgenology 2007, 189: w169. PMID: 17715089, DOI: 10.2214/ajr.07.2252.Peer-Reviewed Original Research
2006
Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, REILLY RF. Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders. Nephrology 2006, 11: 142-146. PMID: 16669977, DOI: 10.1111/j.1440-1797.2006.00544.x.Peer-Reviewed Original ResearchConceptsCalcium-containing bindersSerum phosphorus concentrationLower serum bicarbonate concentrationEnd-stage renal diseaseCalcium-phosphorus productSerum bicarbonate concentrationSevelamer hydrochloridePhosphate bindersCalcium-containing phosphate bindersElevated calcium-phosphorus productHigher serum phosphorus concentrationsMmol2/L2Retrospective chart reviewLong-term efficacyCa-P productLong-term comparative studiesBicarbonate concentrationESRD patientsChart reviewRenal diseaseCalcium loadPatientsLong-term comparisonTarget goalsEfficacy
2004
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal Of Medicine 2004, 350: 1516-1525. PMID: 15071126, DOI: 10.1056/nejmoa031633.Peer-Reviewed Original ResearchConceptsParathyroid hormone levelsPrimary end pointSecondary hyperparathyroidismHormone levelsPlacebo groupCinacalcet groupLow parathyroid hormone levelsSerum calcium-phosphorus productIntact parathyroid hormone levelsEnd pointCalcium-phosphorus productEfficacy assessment phaseParathyroid hormone valuesPatients Receiving HemodialysisPlacebo-controlled trialPercentage of patientsAdverse clinical outcomesCalcium-phosphorus homeostasisCalcium-sensing receptorClinical outcomesVitamin DDaily dosesStandard treatmentHormone valuesCardiovascular disease
2003
Addition of sertraline to other therapies to reduce dialysis‐associated hypotension
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, PERAZELLA MA. Addition of sertraline to other therapies to reduce dialysis‐associated hypotension. Nephrology 2003, 8: 296-301. PMID: 15012700, DOI: 10.1111/j.1440-1797.2003.00216.x.Peer-Reviewed Original ResearchConceptsDialysis-associated hypotensionCentral blood volumePeripheral vascular resistanceBlood pressureCardiac outputBlood volumeEnd-stage renal disease patientsInitiation of dialysisRenal disease patientsDiastolic blood pressureSystolic blood pressureEffects of sertralineTermination of dialysisAddition of sertralineUltrasound dilution techniqueVascular resistanceArterial pressureHaemodynamic measurementsDisease patientsPatientsControl phaseSertralineTherapyDialysisHypotensionImplications of the ADEMEX Trial
Mujais S, Vonesh E, Abu-Alfa A. Implications of the ADEMEX Trial. Contributions To Nephrology 2003, 140: 131-141. PMID: 12800353, DOI: 10.1159/000071433.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2002
Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine
Hoeben H, Abu-Alfa AK, Mahnensmith R, Perazella MA. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. American Journal Of Kidney Diseases 2002, 39: 102-107. PMID: 11774108, DOI: 10.1053/ajkd.2002.29887.Peer-Reviewed Original ResearchConceptsPeripheral vascular resistanceCentral blood volumeDialysis-associated hypotensionCardiac outputIntradialytic hypotensionIntradialytic hemodynamicsCool dialysateEnd-stage renal disease populationTermination of hemodialysisInitiation of hemodialysisMean arterial pressureRenal disease populationUltrasound dilution techniqueVascular resistanceHemodynamic stabilityArterial pressureBlood pressureUltrafiltration volumeDisease populationHypotensionBlood volumePatientsMidodrineHemodialysisHemodynamics
2001
Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate
Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella M. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases 2001, 37: 294-299. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.Peer-Reviewed Original ResearchConceptsHigh dialysate calcium concentrationSevere intradialytic hypotensionDialysate calcium concentrationIntradialytic hypotensionBlood pressureEnd-stage renal disease populationCalcium concentrationLow dialysate calciumSeverity of hypotensionMean arterial pressurePeripheral vascular resistanceIntradialytic blood pressureRenal disease populationProspective crossover studyTreatment of patientsMultiple pathogenic factorsType of therapyDialysate calciumHemodynamic instabilityVascular resistanceHemodynamic stabilityArterial pressureCrossover studyCardiac outputCool dialysate
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors
1996
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
Cruz D, Perazella M, Abu-Alfa A, Mahnensmith R. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? American Journal Of Kidney Diseases 1996, 28: 535-540. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.Peer-Reviewed Original ResearchConceptsChronic hemodialysis patientsEnzyme inhibitor therapyACE inhibitorsHemodialysis patientsInhibitor therapySevere anemiaGroup 2Group 1End-stage renal diseaseExacerbation of anemiaSuppression of angiotensinChronic renal failureCongestive heart failureTherapy of anemiaBone marrow responseSignificant differencesRed blood cell productionRecombinant human EpoRHuEPO responseChronic hemodialysisErythropoietin resistanceRenal transplantationBaseline characteristicsHospital daysRenal failure